Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Division of Medical Oncology/Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Canada.
Ann Oncol. 2022 May;33(5):466-487. doi: 10.1016/j.annonc.2022.02.003. Epub 2022 Feb 14.
The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.
欧洲肿瘤内科学会（ESMO）于 2021 年就表皮生长因子受体（EGFR）突变型非小细胞肺癌进行了一次虚拟的共识制定过程。共识包括一个由 34 名肺癌管理方面的领先专家组成的多学科小组。共识的目的是就当前 ESMO 临床实践指南未详细涵盖且现有证据有限或存在冲突的主题制定建议。确定讨论的主要主题为：（i）组织和生物标志物分析；（ii）早期和局部晚期疾病；（iii）转移性疾病和（iv）临床试验设计、患者视角和杂项。专家小组分为四个工作组，以解决与上述四个主题之一相关的问题。事先审查了相关科学文献。工作组制定建议，然后向全体小组提交进一步讨论和修订，然后进行投票。本文档介绍了制定的建议，包括专家小组讨论的结果、共识建议以及每项建议所依据的证据总结。
